LON:RENE - ReNeuron Group Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 290 +10.00 (+3.57 %) (As of 05/21/2019 04:00 PM ET)Previous CloseGBX 280Today's RangeGBX 279 - GBX 29552-Week RangeGBX 29.50 - GBX 325Volume62,192 shsAverage Volume28,700 shsMarket Capitalization£91.77 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom. Receive RENE News and Ratings via Email Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:RENE Previous Symbol CUSIPN/A CIKN/A Webhttp://www.reneuron.com/ Phone+44-20-38198400Debt Debt-to-Equity RatioN/A Current Ratio6.96 Quick Ratio6.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£900,000.00 Price / Sales101.97 Cash FlowGBX 100.36 per share Price / Cash Flow2.89 Book ValueGBX 100.80 per share Price / Book2.88Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees62 Outstanding Shares31,646,200Market Cap£91.77 million Next Earnings Date6/27/2019 (Estimated) OptionableNot Optionable ReNeuron Group (LON:RENE) Frequently Asked Questions What is ReNeuron Group's stock symbol? ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE." How were ReNeuron Group's earnings last quarter? ReNeuron Group Plc (LON:RENE) issued its quarterly earnings results on Friday, December, 14th. The company reported ($16.80) earnings per share for the quarter. View ReNeuron Group's Earnings History. When is ReNeuron Group's next earnings date? ReNeuron Group is scheduled to release their next quarterly earnings announcement on Thursday, June 27th 2019. View Earnings Estimates for ReNeuron Group. Has ReNeuron Group been receiving favorable news coverage? News stories about RENE stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ReNeuron Group earned a coverage optimism score of 1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of ReNeuron Group's key competitors? Some companies that are related to ReNeuron Group include Kodiak Sciences (KOD), OncoCyte (OCX), Monash IVF Group (MVF), Paradigm Biopharmaceuticals (PAR), OncoCyte (OCX), IMV (IMV), 22nd Century Group (XXII), Horizon Discovery Group (HZD), Emblem (EMC), Rafael (RFL), BELLUS Health (BLU), CEL-SCI (CVM), Enochian Biosciences (ENOB), Bioventix (BVXP) and MediGene (MDG1). What other stocks do shareholders of ReNeuron Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include International Road Dynamics (IRD), Sareum (SAR), ValiRx (VAL), Independent Oil & Gas (IOG), Dignity (DTY), Tri-star Resources (TSTR), Sirius Minerals (SXX), Collagen Solutions (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF). Who are ReNeuron Group's key executives? ReNeuron Group's management team includes the folowing people: Mr. Olav Hellebø, CEO & Director (Age 54)Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)Dr. Randolph Corteling, Head of ResearchMr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs How do I buy shares of ReNeuron Group? Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is ReNeuron Group's stock price today? One share of RENE stock can currently be purchased for approximately GBX 290. How big of a company is ReNeuron Group? ReNeuron Group has a market capitalization of £91.77 million and generates £900,000.00 in revenue each year. ReNeuron Group employs 62 workers across the globe. What is ReNeuron Group's official website? The official website for ReNeuron Group is http://www.reneuron.com/. How can I contact ReNeuron Group? ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400. MarketBeat Community Rating for ReNeuron Group (LON RENE)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 163 (Vote Outperform)Underperform Votes: 103 (Vote Underperform)Total Votes: 266MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe RENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: What is Forex? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.